Member Info for paternostpauper

I echo Kuschall’s post below. Adam H is a long time Val holder who has many times posted of the potential of CLX and even worked as shareholder rep. Check out his Val posts as rhubarbmk2. For a long time he was Val’s key SH. Although I have never met Adam, several friends have confirmed he is a genuine bloke as well as a top scientist.

He was appointed as a non-exec Apta director in Aug ’23 and charman in Sept ’24. Since Adam’ time as a director, Apta has raised in Sept ’23, July’24 and July ’25. He was actually appointed only 3 weeks after an earlier placing in July ’23 to keep the company afloat.

I am delighted for all Apta holders, particularly Fred and a few others who deserve some success. However, some of those holders bought in at over £1 only 3 years ago, so like many Val holders will be underwater. Apta has started to turn the corner just as I expect Val to do shortly.

Mark has been Val CEO since Aug ’24. In Mark’s time as CEO, he has carried out one placing (Dec ’24) to resolve a financial situation he inherited. Mark is transforming Val, just as Adam is doing at Apta.

To those who keep referring to history lessons, the Val of today is a million miles from the Val of yesteryear, or even 12 months ago. Everyone knows how quickly small caps can leap on just one strong RNS. Val has numerous updates pending, any of which could propel Val into warrant territory and beyond.

However, that doesn’t align with Nick’s agenda. He continues to post here trying to supress the SP. I suggest he sticks to posting about Apta on the relevant forum and leave Val holders to savour the coming months.

By the way Nick, for once I’ll be cheering Arsenal this weekend, Lol.

GLA, DYOR, AIMO

Well, a reasonable day yesterday for holders. As expected, Nick sweating. LOL

6 “unknown” trades, tho’ if sorted into chronological order it is reasonable to assume that both the 2.3m and 1m (12.16pm) were both buys, and the other 4 were sells. The 200k “buy“ at 12.28pm would also have been a “sell”.

On that basis, 10.24m buys totalling just under £72k (avg 0.7p) and 8.34m sells totalling £53.8k (avg 64.5p). The buys ranged between 0.645p and 0.793p and the sells between 0.62p and 0.676p.

Due to the spread, the only day traders who could have made a profit were the first two buys of the day. If they bought the 1.5m shares for £9700 and then sold in drips at the seven best prices they could have made a massive £108 profit and still have 14000 shares in hand. Anyone else, would have sold for a LOSS on the day.

Some of the sells may well have bought in a few weeks ago at lower SPs and made a decent profit. I hope so, as once gone….

Val is no longer a trading share. Too many stick fingers holding for gold. All the scaremongering by Nick and his cronies just ain’t working. More to the point, the SP rise was not even on significant news, simply a feelgood factor. The best RNSs are still to come.

Happy days.

GLA, DYOR, AIMO

No longer a trading share with such a wide spread. Buy and hold or look elsewhere.

Happy days

GLA, AIMO, DYOR

Lovely to see those green bars so early in the morning. LOL

Tells you that those posters are having sleepless nights and Mark obviously has them worried. Great stuff!

Val is no longer a one-trick pony – more a thoroughbred!

GLS, DYOR, AIMO

Today’s RNS included the following statement. “A detailed technical and market assessment has been conducted for Val201 as part of a comprehensive review of ValiRx's current and potential assets”.

So what does this £2m market cap hold, asset-wise?

CLX - ValiRx holds 60% of the shares in Cytolytix. The remaining 40% is split between King's College London (20%), and the two academic inventors of CLX001, Martin Ulmschneider and Charles Chen – now at AZN. (RNS 24/10/22). The estimated global annual cost of breast cancer is approx $119 billion, according to a comp study published in JAMA Oncology.

Dundee pro-senescence project - “…We are pleased with the demonstration of activity for the compounds under evaluation ...We are fortunate to be working with Professor Bishop and have worked with her to secure non-dilutive funding to undertake the required work." (RNS 30/1/25)

401 - “Valirx will receive 576000 Ambrose shares with clinical & milestone payments of up to £16m in Valiseek” (of which Val owns 54%). (RNS 20/6/25)

PredictRx - “…the arrangement is strategically important in demonstrating the commercial application of Val's platform and establishing future buyout value.” (RNS 4/8/25)

StingRay - “At the conclusion of the evaluation period, Val has an option to license the technology, under pre-agreed terms, into a Special Purpose Vehicle jointly owned with Stingray. On completion of IND enabling studies, Val's ownership will increase to 75%”.

“The contract is for 12 mnths but we envisage completing the work significantly faster than this.” (RNS 5/8/25)

Other RNS’d collaborations since ME’s appointment (12/8/24):

BioReperia (27/8/24), DLOC Biosystems (9/9/24), Spanios (16/9/24), Xenopat (18/9/24),Ignota (24/9/24), BioRep (7/10/24), Amply Discovery (19/11/24), Altus (29/1/25), Screenin3d (3/2/25), Cellomatics (30/4/25), Dominion (30/4/25 &12/5/25), Omios (3/6/25) & Voxcell (29/6/25).

Mark E has every reason to put in this effort. The CEO’s personal stake is 22,746,187 shares (6.08%) & 20,769,230 warrants. (RNS 30/12/24).

In addition to the value of a state-of-the-art lab, Inaphaea is building more data into the PDC biobank. Mark has already confirmed the data itself is a significant asset in addition to the 470 PDC vials across 66 cancer types. Inaphaea typically get £10k per PDC cell-line upon commercialisation, plus commercial rights entitlement.

Inaphaea also have a range of CAFs, which alone can command up to £6k per vial.

Prior to Mark’s appointment, Val was mainly reliant on legacy assets and an under-utilised, over-staffed team. While cutting costs, he has progressed these assets, with SPV’s now being prepared. Meanwhile, Val is continually expanding into developing areas of oncology: immunotheraphy, personalised medicine, pro-senescence science, the use of ML and AI in Bio research, Lab-on-a-Chip’ tech, repurposing and shortly - vet science & comparative oncology.

Val is n

“The global veterinary oncology market size was estimated at USD 1,568.4 million in 2024 and is projected to reach USD 3,108.9 million by 2030, growing at a CAGR of 12.1% from 2025 to 2030. Key growth drivers include increasing the prevalence of cancer in pets, increasing R&D in pet cancer therapy, and growing focus on animal safety.”

https://lnkd.in/etXEJpWQ

Mark set up the new Advisory Board to explore any potential market opportunities. However, manned with a strong veterinary weighting, it is clear in which field the main focus will be. Having previously capitalised with a $26m Volition deal, he knows the market, its opportunities and how to satisfy those demands.

Dr Heather Wilson Robles, appointed to AB with Cathy and Dr Wheeler, is a clinical oncologist and former President of The Veterinary Cancer Society. Chief Medical Officer at Volition Veterinary Diagnostics and Director of Research at Ethos Discovery, a nonprofit organization focused on advancing veterinary and human medical science through innovative research and clinical trials. It acts as a scientific incubator, developing new diagnostic and therapeutic solutions—especially for complex conditions like cancer—by studying naturally occurring diseases in pets. Ethos Discovery partners with academic institutions, commercial entities, and veterinary hospitals to identify unmet medical needs and test new treatments.

Dr. Robles’ work with canine cancers has advanced understanding of human paediatric oncology, especially in drug development and treatment resistance. She has received over $8.1 million in research funding from a variety of sources.

Hardly a run-of-the-mill appointment!

GLA,DYOR,AIMO

PS When filtering this poster, bear in mind he can't spell 'investor' so initially slipped thru' the net LOL

Always a positive sign when multiple green bars start appearing on the screen. LOL

Uncanny, check out the Ambrose appointment posted on Linkedin. Looks like full steam ahead.

LSE playing up so I can't post links or copy and paste.

That sounds reasonable, Gilders. Why not let it play out and make a decision in say 3-4 months.

For Nick, that doesn’t work as he desperately wants the SP to drop to buy back in and it just ain’t happening.

A very happy holder!

GLA, AIMO, DYOR

Wow, Nick. Really hitting home, isn’t it?

6 weeks, LOL. What’s the betting you are posting 2-3 times a day trying to get back in before news hits.

You’ve had a good run. Accept Val is no longer for trading and move on.

A top CEO determines objectives and sets the direction to achieve them. He leverages all his assets, both material and human to help maximise the company’s potential, even more essential in the early stages of growth. Mark has transformed Val in just 12 months. A select group of individuals have been moulded into an effective team, working together and with other parties to the benefit of all. He believes Val can capitalise on new opportunities in developing oncology science and leverage existing assets to maximum effect.

The Omios evaluation is the first commercial CLX evaluation and also the first to use a virus as a delivery platform. However, like the Altus and recent Voxcell evaluations, aims to demonstrate the versatility of CLX and synergistic effects when used with other drugs and treatments. At every opportunity, our CEO promotes our lead asset and continually builds more value into the imminent SPV.

What’s the big deal with CLX?

• It is a cytolytic peptide designed to selectively destroy cancer cells by creating pores in cancer cell membranes, causing lysis (cell death) and allows other drugs (like small molecules or immunotherapies) to penetrate more effectively, making CLX ideal for combination therapies.

• “As well as killing cancer cells, CLX releases antigens that stimulate the immune system, potentially creating a synergy with immuno-oncology therapeutic approaches.”

• CLX targets cancer cells without harming healthy tissue.

• Unlike many oncolytic peptides that require direct injection into tumours, Cytolytix is designed for intravenous administration, making it more versatile for metastatic cancers – no hiding place, CLX will find those nasty cells!

Does the market need CLX? - It primarily targets triple negative breast cancer (TNBC), a high unmet clinical need with 2.3m annual cases of breast cancer of which15-20% are triple negative, highly aggressive and metastatic (ie not confined to original site). CLX may be extended into prostate and other solid cancers. The market for TNBC alone is estimated at up to $1b and rising.

Does Valirx own CLX001? - On 24/10/22 Val released an RNS confirming the set-up of a new subsidiary company, Cytolytix, and an IP License Agreement with King's College, London. The partnership blends academic innovation with commercial execution. King’s brings the foundational science, while Val drives regulatory and clinical strategy. Val holds 60% of the shares in Cytolytix. The remaining 40% is split between King's (20%), and the two inventors, Prof Martin Ulmschneider and Charles Chen (now a Snr Scientist at AZN).

What’s next for CLX? - Several formulations are currently being trialled so decisions on that, filing patents then generating the data to support those patents before finalising the SPV. To top it all, in the webinar Mark admitted discussions regarding early partnering had already taken place with more planned.

GLA, DYOR, AIMO

Enjoy your break, Uncanny.

29 Val posts by Nick MTD trying to sow FUD. Shameful, even by his standards.

Getting desperate to get back on board but with the spread would only be rejoining around his last exit. What a shame.

Meanwhile, Stephen W paddling in Barbados, while Nick plays padel in the rain. LOL

GLA, AIMO, DYOR

Oh. now you mention it. LOL

A good find, Uncanny.

However, one paragraph in this Catsci article by Jordan Fletcher, sums up the peptide market nicely: https://catsci.com/library/peptides-riding-a-renewed-wave-of-optimism/

“Startups with peptide platforms are thriving, academic funding bodies are supporting research around peptides, and large pharma companies are investing heavily in internal peptide capabilities.”

Now, if only Val expanded into peptides. 😃

During Mark’s tenure, Val has put both the Imperial College and Barcelona evaluations on ice. Not that they didn’t hold promise, but neither complied with Val’s Vision “to accelerate transitional research into clinical candidates”. If Mark can’t envisage a program becoming profitable short/mid term, it is shelved.

The StingRay project hasn’t been shelved, in fact, Val is now committing up to a further £56k focussing on lead drug compounds. So, the chaff has been removed and the focus is now on the most promising candidates and a potential joint SPV with StingRay.

While the agreement spans 12 months, “we envisage completing the work significantly faster than this” (approx. 6 months in the accompanying video). However, Mark has built-in a safety net where Val can still benefit even if they decide not to pursue the project or StingRay partners elsewhere. As you would expect with our CEO’s commercial experience and awareness, he covers all bases.

In yesterday’s Dominion RNS, Mark added “although initial revenues under the Agreement are expected to be modest, the arrangement is strategically important in demonstrating the commercial application of ValiRx's platform and establishing future buyout value.” No attempt to overstate or mislead, as a scientist he works on facts not speculation. What a pleasant change.

AIMO,GLA,DYOR

It was a good decision to block the naysayers. So much rubbish posted daily by these bored individuals with absolutely nothing to contribute.

However, I have not binned Nick as I’m savouring his mounting desperation to drive the SP lower and get back into the game.

Strange innit! Green bars everywhere, yet lots of blue on the trades. LOL

More green bars here than on a pub crawl in Dublin.  🤣 🤣 🤣

The 3rd Dominion RNS since the end of April. Clearly, both Inaphaea and Dominion have a good partnership which should prove fruitful over the coming years. This latest RNS capitalises on the movement towards personalised treatment and the tailoring of medical treatment to the individual characteristics of each patient. Both Inaphaea and Dominion can boast of an extensive and growing biobank. Several times, Mark has emphasised the ‘data’ aspect is as valuable as the vials themselves and every collaboration builds more data into the biobank. This new PredictRx platform capitalises on that asset and for minimal outlay increases the offering of both companies.

The collaboration with Dominion is proving productive on multiple fronts. In addition to the biobanks and PredictRx platform, the repurposing exercise should see several promising candidates emerge from the 3000 drugs being screened. In the June webinar: ” We are seeing activity in, say 250 or so of the models. These are already FDA approved, have safety data and much later stage clinical data. We need select the best of those and do a small amount of validation work then we have IP we can (jointly) file around and look to partner those”.

Valirx is continually expanding into developing areas of oncology; immunotheraphy, personalised medicine, the use of machine-learning and AI in Bio research, Lab-on-a-Chip’ tech, and repurposed assets. The Advisory Board has a heavy weighting towards veterinary science so comparative oncology is in the pipeline. Never heard of pro-senescence treatments or LMTK3 -don’t worry you will. Val has them all covered.